search
Back to results

L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics (SANDIA)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
L-citrulline
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring L-citrulline, ADMA, Asthma, Obesity

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients, 18-75 yrs old, from all racial/ethnic backgrounds
  • Diagnosis of asthma for >1 yr
  • BMI ≥ 30
  • Baseline pre-bronchodilator FEV1 between 60 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol
  • Smoking history <20 pack years and no smoking in the last year
  • Able to identify age of asthma onset

Exclusion Criteria:

  • Respiratory tract infection within the last 4 weeks;
  • Oral CS burst within the last 4 weeks or regular systemic CS use
  • Hospitalization within the last 3 months
  • ER visit within the 4 weeks
  • Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes
  • Current smoking or within the previous 12 months
  • Current use of statins for the past 30 days (Statins lower ADMA levels)
  • Pregnancy
  • Intolerance or allergy to L-arginine or L-citrulline
  • Phosphodiesterase inhibitors
  • Taking oral nitrates

Sites / Locations

  • Asthma Institute, University of Pittsburgh

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

L-citrulline

Placebo

Arm Description

3-gr/day of L-citrulline effervescent powder mix

3 gr of Placebo/day matching L-citrulline effervescent powder

Outcomes

Primary Outcome Measures

Exhaled nitric oxide
Patients will be randomized to 1 week of 3 g of L-citrulline/day vs matching placebo, The outcome is the pre to post intervention change in exhaled NO

Secondary Outcome Measures

Sputum and plasma L-arginine/ADMA levels
This outcome compares the pre to post L-citrulline supplementation changes in sputum and plasma L-arginine/ADMA

Full Information

First Posted
October 16, 2012
Last Updated
June 29, 2017
Sponsor
University of Pittsburgh
search

1. Study Identification

Unique Protocol Identification Number
NCT01715844
Brief Title
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
Acronym
SANDIA
Official Title
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
September 7, 2013 (Actual)
Primary Completion Date
June 1, 2016 (Actual)
Study Completion Date
June 1, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In people who develop asthma after the age of 12 and who are also overweigh, there can be an increased burden of asthma symptoms, more flare-ups, and poorly-controlled asthma when compared to normal weight asthmatics. Certain factors are more abundant in the blood of individuals who are obese. One such factor is derived from the metabolism of an amino acid found in your diet, which is known as L-arginine (Amino acids are most commonly known as the building blocks of proteins, the same as the proteins found in food). This factor is called asymmetric dimethylarginine or ADMA. The balance of L-arginine to ADMA may be important to the health of subjects with asthma. The balance between L-arginine and ADMA plays an important role in producing nitric oxide (NO) in the airways. NO is normally produced in the lung and plays a major role in maintaining airways open and functioning normally. Our research has shown that in subjects with asthma who are overweight and developed asthma later in life, the combination of low L-arginine and high ADMA, may lead to lower NO levels. We are asking participants in this study to take L-citrulline, which is converted to L-arginine by your body, as a supplement for a period of one week. We anticipate that L-citrulline will restore NO levels in the airways, by increasing the ratio of L-arginine to ADMA

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
L-citrulline, ADMA, Asthma, Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
L-citrulline
Arm Type
Active Comparator
Arm Description
3-gr/day of L-citrulline effervescent powder mix
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
3 gr of Placebo/day matching L-citrulline effervescent powder
Intervention Type
Dietary Supplement
Intervention Name(s)
L-citrulline
Other Intervention Name(s)
L-citrulline 3 gr efervescent powder
Intervention Description
Patients will take 3-gr of L-citrulline/day for 7 days
Primary Outcome Measure Information:
Title
Exhaled nitric oxide
Description
Patients will be randomized to 1 week of 3 g of L-citrulline/day vs matching placebo, The outcome is the pre to post intervention change in exhaled NO
Time Frame
1 week
Secondary Outcome Measure Information:
Title
Sputum and plasma L-arginine/ADMA levels
Description
This outcome compares the pre to post L-citrulline supplementation changes in sputum and plasma L-arginine/ADMA
Time Frame
1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients, 18-75 yrs old, from all racial/ethnic backgrounds Diagnosis of asthma for >1 yr BMI ≥ 30 Baseline pre-bronchodilator FEV1 between 60 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol Smoking history <20 pack years and no smoking in the last year Able to identify age of asthma onset Exclusion Criteria: Respiratory tract infection within the last 4 weeks; Oral CS burst within the last 4 weeks or regular systemic CS use Hospitalization within the last 3 months ER visit within the 4 weeks Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes Current smoking or within the previous 12 months Current use of statins for the past 30 days (Statins lower ADMA levels) Pregnancy Intolerance or allergy to L-arginine or L-citrulline Phosphodiesterase inhibitors Taking oral nitrates
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernando Holguin, MD MPH
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asthma Institute, University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31714895
Citation
Holguin F, Grasemann H, Sharma S, Winnica D, Wasil K, Smith V, Cruse MH, Perez N, Coleman E, Scialla TJ, Que LG. L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight. 2019 Dec 19;4(24):e131733. doi: 10.1172/jci.insight.131733.
Results Reference
derived

Learn more about this trial

L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics

We'll reach out to this number within 24 hrs